GSA Capital Partners’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
GSA Capital Partners's NPCE Position: Q3 2026 in Review
GSA Capital Partners reduced its Neuropace (NPCE) stake by 62% in Q3 2026, selling an estimated $1.06M and leaving 44,005 shares worth $606K. The position accounts for 0.04% of the portfolio, ranked #928.
GSA Capital Partners first reported a position in NPCE in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.84M in Q2 2026. 99 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.
- GSA Capital Partners held 44,005 shares of Neuropace worth $606K as of Q3 2026.
- GSA Capital Partners sold 71,530 Neuropace shares in Q3 2026, an estimated $1.06M.
- Neuropace made up 0.04% of GSA Capital Partners's portfolio in Q3 2026, its #928 holding.
- GSA Capital Partners first reported a position in Neuropace in Q4 2024 and has held it in 8 quarters since.
- GSA Capital Partners's Neuropace position peaked at $1.84M in Q2 2026.
- 99 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.